Wednesday 12 August 2020 4:24 am

Making it work: Why we need to start talking about who gets access to a coronavirus vaccine

Dr Farley Cleghorn leads the health practice for Palladium

There is an unprecedented international scientific effort underway to develop an effective vaccine for SARS CoV-2 — the cause of Covid-19 — and we are all desperate for some good news. 

I have spent my life fighting infectious diseases around the world, from HIV to SARS to Ebola. Unfortunately, our collective track record for speedy vaccine development is, in truth, uneven and disappointing. The mumps vaccine holds the record at over four years, and we are yet to find one for HIV. 

And yet the science behind a coronavirus vaccine is not as daunting.

Read more: Russia names new vaccine after iconic satellite Sputnik

Leaving aside the Russian claims of a vaccine success, two of the most promising initiatives are in the UK and US. Last month, US pharmaceutical company Moderna began phase III trials of its vaccine. And at Oxford University, the first human trials have shown that the vaccine under development did not prompt any serious side effects and elicited both antibody and T cell immune responses.

This positive news has led to UK media headlines speculating that we could have a Covid-19 vaccine rolled out by Christmas. Recruitment is already underway for large scale trials which are due to begin in the coming weeks. 

However, developing a vaccine is only half the battle. The toughest trials lie ahead in ensuring equal and affordable access to any successful vaccine to the entire world.  

We have yet to create a proven model for vaccine development and distribution during a pandemic, let alone the kind that will be required by the entire global population. As an international medical and political community, we must ensure that any eventual treatment is free from the narrow and selfish calculations of “vaccine nationalism”. 

There are multiple perils to be considered, from cost and vaccine hoarding to price gouging and lack of access for the most vulnerable in our societies. 

The issues of access and pricing are even more acute in poorer countries where it takes much longer to close vaccine coverage gaps. People in these countries will be at the back of the line.

While the impact of the virus has been far from equitable, it is our societal responsibility as global citizens to assure access to proven treatments and preventatives like vaccines to all who need them. 

I am concerned at the general assumption that coronavirus vaccines will be available free of charge to all and that pharmaceutical companies are only seeking to recover their costs. This is not the case. Stephane Bancel, chief executive of US biotech company Moderna, has been explicit about his plans to make a profit. Others are no doubt thinking the same, even if they are not saying it.

How will developing countries access a proven vaccine, and what will they pay? Many in the medical and research community would like to see an explicit commitment to free global distribution of a Covid-19 vaccination treatment, and more inclusive conversations happening right now about how that might work.   

The science behind a coronavirus vaccine looks promising, and the investment towards one is impressive — with $10–15bn invested in the US alone. But there is a long way to go from development to universal access. And right now, there remains a significant gap between the rhetoric and the reality.

Read more: UK and Valneva agree to set up coronavirus vaccine facility in Scotland

Main image credit: Getty

City A.M.'s opinion pages are a place for thought-provoking views and debate. These views are not necessarily shared by City A.M.